

BDNFIV promoter methylation and antidepressant action: a complex interplay

Hansi Pathak (✉ Pathak.hansi@mh-hannover.de)

Hannover Medical School (MHH)

Anton Borchert

Hannover Medical School (MHH)

Sara Garaali

Alexandra Burkert

Hannover Medical School (MHH)

Helge Frieling

Hannover Medical School (MHH)

Research Article

Keywords: BDNFIV promoter, Methylation, Antidepressants, Site directed mutagenesis, MeCP2, CREB

Posted Date: June 7th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1688635/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: No competing interests reported.

Version of Record: A version of this preprint was published at Clinical Epigenetics on December 26th, 2022. See the published version at <https://doi.org/10.1186/s13148-022-01415-3>.

Abstract

Background:

BDNFIV promoter methylation is a potential biomarker for treatment response to antidepressants in MDD. We have previously shown CpG-87 methylation as a successful biomarker for prediction of non-response to monoaminergic antidepressants like the SSRI Fluoxetine or the SNRI Venlafaxine. This study aimed to dissect the biological evidence and mechanisms for functionality of CpG-87 methylation in a cell culture model.

Results:

We observed a significant interaction between methylation and antidepressant mediated transcriptional activity in BDNFIV promoter. In addition, antidepressant treatment increased the BDNFIV methylation in a concentration dependent manner. Further single CpG methylation of -87 did not change the promoter activity, but methylation of CREB domain CpG-39 increased the transcriptional activity in an antidepressant dependent manner. Interestingly, DNMT3a over-expression also increases the BDNFIV transcription and more so in Venlafaxine treated cells.

Conclusions:

The study strengthens the previously reported association between antidepressant treatment and BDNFIV methylation as well as hints towards the mechanism of action. We argue that potential CpG methylation biomarkers display a complex synergy with the molecular changes at the neighboring CpG positions, thus highlighting the importance of epiallele analyses.

Background

Major depressive disorder (MDD) is a multifaceted disease disorder that imposes a measurable burden on society. Over the past decade, it has been widely accepted that symptoms and manifestations of depression between individuals and cannot be empirically explained by dysfunction of any particular biological process. Although matching the pathology to a certain extent with the molecules and pathways involved can draw a subjective classification, more evidence is needed to extrapolate findings to the therapeutic regimens (1). The major challenge in treating the patients with MDD is the inherent heterogeneity in response rates towards the commonly used antidepressants, the serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) (2).

Therefore, it is imperative to work systematically towards understanding the underlying causative and predictive biological differences in the patients.

Brain-derived neurotrophic factor (BDNF) mediated signaling cascades is implicated in neuronal differentiation, synaptic plasticity and neurotransmission, claiming BDNF as a central molecule for various interventions for depression as well as other psychiatric disorders. Compelling evidence is

available towards disruption of BDNF gene in manifesting the depressive behaviors from both animal and patient studies (3). BDNF up-regulation is one of the key functional phenomena to downstream pathways of antidepressant drugs (4) (5).

Transcription of BDNF is an intricate example of temporal and spatial regulation. The BDNF gene contains 11 exons with multiple splicing sites (6). The last exon codes for BDNF protein and contains two poly (A) stretches resulting in a protein with a short or long 3' UTR. Remaining 10 exons containing independent internal promoters that allow the transcription of 13 different transcripts each containing a unique 5' UTR proximate to the coding exon (7). Transcription factors, epigenetic modifiers and RNA binding proteins work in synchrony to regulate, modulate and fine-tune the expression of specific BDNF transcript in response to developmental cues and also various environmental stimuli (8).

Neuronal activity dependent calcium influx is important to process and store the information in response to environmental stimuli. BDNF exon I and IV transcription is regulated by calcium dependent transcription factors, cAMP response element binding protein (CREB), upstream stimulating factor (USF) (9). CREB is a histone deacetylase and recruits other transcriptional activators, upregulating the transcription of BDNF transcripts (10). In addition, histone modification like H3K4me3 mark has been associated with active BDNF promoter (11) (12).

Interestingly, transcriptional regulation of BDNF, in absence of any stimuli occurs via CpG methylation or H3K27 trimethylation. Methylation-dependent regulation has been reported for BDNF exon I, IV, VI and IX (13) (14, 15).

MDD has a mere heredity of 37% and therefore the onset, development and the progression of disease has been shown to be primarily mediated via epigenetic mechanisms (16). Social factors like, early life stress, childhood maltreatment and maternal separation change BDNF promoter methylation (17). Serum BDNF levels before treatment have been associated with SSRI response in depression (18). CpG specific hyper- and hypomethylation of exon I and IV promoter has been reported in various psychiatric disorders including MDD. Although it remains inconclusive whether antidepressants alter BDNF methylation, differences in the CpG methylation of BDNF internal promoters has been presented as a biomarker for therapy response (19) (20).

We have previously shown that the hypermethylation at CpG-87 (from the transcriptional start site) can successfully predict the non-response to antidepressant therapy (21). This finding has been replicated in a larger cohort of moderate to severely depressed patients, while it could not be replicated for the patients with mild or minor depression (22). Similar findings have been published in a Chinese cohort (23). In our first report, we also provided first in vitro data on transcriptional activity of the BDNF promoter. Antidepressant incubation with Fluoxetine (SSRI) or Venlafaxine (SNRI) led to a reduced activity in a dual-luciferase reporter assay. This down-regulation was specific to unmethylated promoter fragment.

Here, we aim to provide a more detailed insight into the complex interplay of single CpG methylation and antidepressant effects on the BDNFIV promoter activity and BDNF expression.

Results

1. Transcriptional activity of BDNF correlates with whole promoter methylation:

We cloned BDNF exon IV promoter region in a CpG free vector upstream of luciferase gene and analyzed the effect of antidepressants on the transcriptional activity. This experiment replicates the findings from our previous paper (Tadić et al. 2014). We observed a decrease of the BDNF exon IV transcription of unmethylated promoter ($F_{(1,50)} = 11.35$; $P = 0.0015$) in SH-SY5Y neuroblastoma cell line after treatment with antidepressants. The observed reduction was significant for Venlafaxine, Lithium carbonate, Fluoxetine, and Mirtazapine ($P = 0.05$). Interestingly, the antidepressant-induced reduction in BDNFIV transcription was not seen in methylated promoter, thereby explaining a significant interaction between methylation and antidepressant on the promoter activity ($F_{(4,50)} = 4.059$; $P = 0.0063$). An overall reduction of promoter activity was observed in methylated promoter construct ($F_{(4,50)} = 5.615$; $P = 0.0008$) (Fig. 2).

2. Effect of single CpG methylation on BDNF transcriptional regulation:

Clinical data from our previous studies highlighted the importance of CpG-87 methylation for the efficacy of ADs. Patients with methylated CpG-87 showed an increase in BDNF plasma levels after 14 days of treatment. To model the clinical effect of CpG-87, we mutated the cytosines (-87, -39 and -35) to methylated cytosines in BDNFIV-pCpGL construct and compared it to control construct. Additionally, we incubated transfected cells with Venlafaxine and Fluoxetine at the given concentrations for 48 h and harvested cells for luciferase assay. We observed a significant overall effect of methylation ($F_{(3,151)} = 49.41$; $P < 0.0001$). No significant effect of ADs was observed ($F_{(4,151)} = 2.23$; $P = 0.06$).

We observed an interaction between CpG methylation and AD treatment ($F_{(12,151)} = 1.86$; $P = 0.043$). This effect was mainly driven by CpG-39 methylation, as the methylated construct showed significant differences in promoter activity in comparison to BDNFIV unmethylated control only upon AD treatment (Venlafaxine 10 μ M, $P < 0.01$; Venlafaxine 50 μ M, Fluoxetine 5 μ M and 10 μ M, $P < 0.0001$) (Fig. 3).

3. Effect of antidepressants of BDNF methylation levels:

To test the effect of Venlafaxine and Fluoxetine on BDNFIV promoter methylation in a drug naïve environment, we incubated SHSY-5Y cells at two different concentrations (Venlafaxine 10 μ M and 50 μ M; Fluoxetine 5 μ M and 10 μ M) of drugs and harvested cells at four different time points (0.5 h, 2 h, 24 h and 48 h).

We used a linear mixed model computing methylation as a dependent variable and CpG position, drugs, concentration and time point as factors. We observed a significant effect of CpG position ($F_{(10,1301)} =$

69.482; $P < 0.0001$). A significant effect of drugs was found on the BDNFIV methylation ($F_{(1,1301)} = 5.44$; $P = 0.02$). Venlafaxine mainly drove this effect (Fig. 4). The drug concentration had a significant effect on the methylation for both Venlafaxine ($F_{(1,241)} = 13.90$; $P < 0.0001$) and Fluoxetine ($F_{(1,276)} = 5.706$; $P = 0.025$). No overall effect of time point was observed, but a significant change in methylation occurred over time in Fluoxetine treated cells ($F_{(3,276)} = 2.789$; $P = 0.041$) (data not shown).

4. Effect of DNMT overexpression on BDNF methylation and transcriptional regulation

To get an insight into methylation and BDNF exon IV transcription, we co-transfected the luciferase construct harboring the BDNF promoter with DNMT3a, DNMT3b and DNMT1 mammalian expression vectors and their empty vector controls pHTC (DNMT1) and pCDNA3 (DNMT3a and 3b). We found that DNMT3a increases the BDNFIV promoter activity whereas DNMT3b and DNMT1 have no effect.

Further, we treated the transfected cells with ADs to investigate, if overexpression of methyltransferases has any effect on BDNF transcriptional activity in the presence of ADs, we observed significant effect of the drugs ($F_{(2,24)} = 9.33$; $P = 0.001$). The DNMT3a mediated increase on promoter activity was replicable ($F_{(3,24)} = 29.03$; $P < 0.0001$) (Fig. 5a **and b**).

Additionally, we sequenced the cells transfected with DNMTs for methylation analysis to address, if DNMT overexpression has a direct effect on BDNFIV CpG methylation. We also used nanaomycin as a chemical modulator as it has been shown to inhibit DNMT3b. We observed no significant effect of DNMT overexpression or nanaomycin treatment on BDNFIV methylation.

Discussion

BDNF exon IV promoter activity is regulated by methylation in a CpG dependent manner in the absence of neuronal activity (8). BDNF exon IV promoter methylation has been associated with multiple psychiatric disorders along with MDD (19) as well as treatment response to ADs (24) and other available therapy regiments (25). Previous work from our lab has confirmed the CpG-87 hypomethylation as a biomarker for unsuccessful AD treatment in two different studies (21, 22). This work aimed to explore the link between AD action and CpG-87 methylation mechanistically.

To understand the effect of ADs, methylation and their interaction on the transcriptional activity of BDNF exon IV, we cloned BDNF exon IV promoter region in a CpG-free luciferase vector (26) and transfected it into a neuroblastoma cell line SH-SY5Y and treated them with ADs 24 h after transfection for 48 h. The ADs decreased BDNF exon IV promoter activity and this effect was nullified by methylation arguing in favor of a possible link between antidepressant mediated BDNF increase in serum of patients harbouring methylation at CpG-87 locus. These findings corroborated with our previous study where we used the luciferase vector (Promega) containing CpGs demonstrating that the reduction in the promoter activity is due to the CpG methylation of exon IV promoter and not the vector itself. It must be noted that we

methylated the promoter fragment using bacterial methylase MssI, thereby methylating every CpG in the promoter to approximately 90% rendering our system far from physiological.

Linear effect of pharmacological treatments on BDNF promoter methylation has not been clearly elucidated, mainly because of lack of pre-treatment methylation data from the patients and lack of drug naïve cohorts (19).

The clinical data from our lab shows that antidepressants do not change the methylation over 6 weeks of treatment (21). This patient cohort did not contain any drug naïve patients and therefore we could have missed potential AD mediated changes in methylation. To address this in vitro, we incubated SH-SY5Y cells with ADs and analyzed the CpG methylation of BDNF promoter. Both Venlafaxine and Fluoxetine increased the mean promoter methylation in a concentration dependent manner. We did not observe any change in the methylation of CpG-87 upon treatment, suggesting that the disease does not directly modulate CpG-87 or treatment itself. CpG-147, CpG-66, CpG-39 and CpG-35 (suppl. Figure 1) drove the differences in the mean methylation. Our data justify the scope for further studies investigating the molecular mechanisms underlying the antidepressant moderated epigenetic changes.

Further, to differentiate the regulatory effect of methylation of individual CpGs from the whole promoter, we mutated the CpGs of interest to methylated CpGs in the BDNFIV-pCpGL basic construct and performed luciferase assays with or without ADs. We included CpG-87 to model the clinical findings and CpG-35 and -39 due to their proximity with CRE (CREB binding element). CREB has been shown to regulate BDNF protein (27–29) and is involved in antidepressant response (30). We observed no difference in the BDNF exon IV promoter activity upon methylating CpG-35, and -87 in comparison to the unmethylated controls, but CpG-39 methylation increased the transcriptional activity of the promoter. Further plasmid harboring methylated CpG-39 showed a significant increase in promoter activity in the Venlafaxine and Fluoxetine treated cells, suggesting yet again possible drug-methylation interaction. The role of methyl CpG binding protein (MeCP2) has been implicated in depression and more so as a BDNF repressor in resting neurons. MeCP2 can bind to both methylated cytosine (5mC) and hydroxylated methyl cytosine (5hmC), thereby acting as both transcriptional repressor and activator (31). Calcium influx induced neuronal depolarization phosphorylates MeCP2 at specific serine and threonine residues, facilitating its multidirectional role as a regulator (32).

MeCP2 physically and functionally interact with CREB facilitating to the interaction with CRE on the active promoters (33). Therefore, we speculate that this increase in transcriptional activity can be due to enhanced MECP2-CREB complex recruitment to the promoter. We conclude that CpG-87 methylation does not directly increase BDNFIV transcription. A unique population of cells might contribute to the association of positive treatment response to the methylation (1–5%) at this position (measured in blood), which can be identified by emerging techniques like single cell epigenomics (34). Due to technical limitation, we could only methylate single CpG at a time, so we did not account for permutation and combination of methylation patterns that probably exist in the patients.. We will be sequencing a larger

cohort of MDD patients using Oxford Nanopore Technologies that allows single strand methylation analysis that can dissect complex epi-allelic methylation methylation patterns.

DNA methyltransferases specifically methylate regulatory CpGs and modulate gene transcription. A suggestive link exists between DNMTs expression and MDD in the literature (35). To address whether the AD dependent BDNF increase in serum/plasma levels of patients and animals is associated with in vitro methylation changes, we overexpressed DNMTs and treated the cells with ADs. Of the methyltransferases, only DNMT3a increased exon IV activity in control and Venlafaxine treated cells. Interestingly, of the two de novo methyltransferases, DNMT3a is expressed in adult brain, whereas DNMT3b is only found in neural progenitor cells (17). When we bisulfite-sequenced the DNMT overexpressed cells, we did not observe any change in the CpG methylation at BDNF exon IV promoter. Taken together, our findings suggest an indirect effect of DNMT3a overexpression on increase in BDNF IV promoter activity. It will be very interesting to get a deeper insight into the expression pattern of DNMTs in the responders and non-responders.

Our system relies on artificially curated methylation marks that do not reflect the complex scenario in vitro. Therefore, it will be interesting to use Cas9 mediated methylation editing by recruiting methyl modifiers (DNMT/TET) to study the interaction between BDNFIV methylation and antidepressant action on its regulation. Another limitation of the study is that we used a neuroblastoma cell line, thus lacking the communication between different cell types that is essential for antidepressant action. Therefore, we plan to replicate the findings in a mixed cell culture model consisting neurons, astrocytes and myelinating oligodendrocytes.

Conclusions

Our study provides evidence for AD dependent methylation changes on the BDNFIV promoter and emphasizes the importance of studying such interactions in the drug naïve cohorts of MDD patients. It also describes the functional methylation changes that provide a cross talk with AD mediated increase in BDNFIV promoter activity. Further, we highlight the importance of studying DNMTs, especially DNMT3a in context of MDD.

Methods

Cell culture

Human neuroblastoma cell-line SH-SY5Y (ATCC, Wesel) was cultured in DMEM-Ham's F12 medium 1:1 (Biochrom AG, Berlin) supplemented with 10% FBS Superior (Biochrom AG, Berlin) and 1% penicillin/streptomycin (PAN Biotech GmbH, Aidenbach). Cells were maintained at 37°C in a humidified atmosphere of 5% CO₂ in atmosphere. Cells were incubated with indicated concentration and for indicated time with the drugs.

Insert amplification and Cloning

BDNF exon IV promoter region (GRCh38; chr11: 27701325–27702402) was amplified (primers: Inf-BDNF-pCpGL Fw/Rv) from the genomic DNA using KOD Hot Start Taq DNA Polymerase (Novagen, Merck Chemicals, Darmstadt, Germany). Primers contained pCpGL CpG-free luciferase vector specific overhangs (red) that were adapted to the PCR product. The 1172 bp fragment with adapter sequences was cloned into HindIII HF-linearized pCpGL firefly luciferase reporter plasmid (26) by recombination using In-Fusion® HD Cloning Kit (Clontech, cat. no. 639648). Similarly, DNA methyltransferase 1 (DNMT1) cDNA were PCR amplified (primers: Inf-DNMT1-halo Fw and Rv) from a mixture of human cell line cDNA using KOD Hot Start Taq DNA Polymerase and cloned in pHTC HaloTag®CMV-neo Vector (Promega, cat. no. G7711). The plasmids pcDNA3/Myc-DNMT3a and pcDNA3/Myc-DNMT3b were gifts from Arthur Riggs (Addgene, cat. no. 35521 and cat. no. 35522, respectively (36)). Plasmids were transformed in NEB alpha competent cells except pCpGLempty and pCpGL-BDNFIV that were transformed in piR1 Competent E. coli (Invitrogen) with 5 µL recombined plasmid and plated on LB-Agar containing 100 µg/mL Ampicillin: Grown colonies were transferred to 3 mL LB-Amp-Medium and plasmids were isolated using the NucleoSpin Plasmid Kit (Macherey-Nagel, Düren). After verifying the plasmids containing the hBDNF IV promoter region by sequencing (primer: pCpGL-seq_Fw), DNA-purification was done using endotoxine-free plasmid isolation kit (NucleoBond Xtra Midi EF Kit; Macherey-Nagel, Düren). Expression of DNMT1, DNMT3a and DNMT3b was validated by western blotting (data not shown). Refer to table 1 for primer sequences. The underlined sequence is gene specific.

In vitro-Methylation of BDNF IV promoter construct

The pCpGL-BDNF IV promoter reporter (4 µg) was incubated (4 h at 37°C) with CpG Methyltransferase M.SssI (20 U; New England Biolabs, Ipswich, MA) in buffer containing 640 µM S-adenosylmethionine (New England Biolabs, Ipswich, MA). Subsequently, the methylated plasmid was purified with Nucleospin Plasmid Kit (Macherey-Nagel, Düren).

Site-directed mutagenesis

CpGs-87, -39 and - 35 were methylated using the Q5 Site-Directed Mutagenesis Kit (NEB, E0554) following manufacturer's protocol. Briefly, the pCpGL-BDNFIV promoter reporter construct was reverse amplified using mut - 87, mut - 39 and mut - 35 or mut-cntrl Fw/Rv primers and Q5 Hot Start High-Fidelity DNA Polymerase. The primers were back-to-back primers and were designed using NEBaseChanger. Cytosine at desired position was replaced with methylated cytosine. Multiple reactions were pooled to gain a sufficient starting DNA amount. The PCR product was combined with the KLD Mix, containing a blend of kinase, ligase and DpnI enzymes, and was incubated for 15 minutes. After KLD treatment, the reaction was purified using NucleoSpin Plasmid Kit (Macherey-Nagel) and was used directly for transfection. The efficiency of mutagenesis was assessed by Sanger sequencing. All three CpGs were about 60% methylated. Refer to table 1 for primer sequences

Transfection and Luciferase-based reporter gene assays

1.5 x 10⁵ SH-SY5Y cells were plated in 96 well plates for 24 h before transfection. 100 ng/well of BDNF IV promoter luciferase reporter plasmid or methylated BDNF IV promoter luciferase reporter plasmid were

cotransfected with 2 ng/well pGL4.74 [hRluc/TK] renilla luciferase control plasmid (Promega, Madison, WI) for normalization (3 columns per reporter plasmid) using Lipofectamine 3000 (company). 50 ng of the luciferase constructs was used for transfection, both for control and mutated CpGs. Cells were harvested 48 h after transfection. For DNMT overexpression experiments, 25 ng of DNA were used for transfection for both DNMTs and empty vectors. Antidepressants were added 12 h post transfection. After incubation over 48 h cells were lysed and luminescence was measured using the Dual Luciferase Reporter Assay System (Promega, Madison) and the GloMax Multi + Luminometer (Promega, Madison), according to the manufacturer's protocol.

Luciferase assays

Post transfection, media was removed and cells were washed with PBS. Assay was performed using Dual Luciferase Reporter Assay System (Promega) and the luminescence was recorded using double injector program on GloMax-Multi Detection System. Assay was applied in triplicates and was repeated 3 times. For analysis, firefly readings were normalized by the respective renilla luminescence readings and normalized values were imported to GraphPad Prism 5 (Graph Pad Inc., San Diego, CA).

Bisulfite sequencing of the BDNF exon IV promoter region

Genomic DNA was extracted from cells using NucleoMag Blood 200 μ L (Macherey-Nagel) according to the manufacturer's protocol. Afterwards, 500 ng of genomic DNA were modified by sodium-bisulfite using the EpiTect® 96 Bisulfite Kit (QIAGEN).

Primers were designed to amplify a region covering a fragment of 277 base pairs (bp) from - 200 to + 77 bp relative to the starting bp of the fourth exon of BDNF (NCBI NC_000011.9: 27723103–27723380) containing 13 CpG sites within the promoter region of BDNF exon IV. To amplify a specific product, a semi-nested polymerase chain reaction (PCR) was performed using 1 μ L bisulfite modified DNA or PCR round 1 product with 0.4 μ L of each primer and 5 μ L HotStarTaq Master Mix (Qiagen) filled to a reaction volume of 10 μ L.

Sequencing of the reverse strand was performed using a BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on an Applied Biosystems® 3500xL Genetic Analyzer (Applied Biosystems; POP-7™ polymer) according to the manufacturer's instructions. Primer sequences are given in table 1 (Amplification: bisBDNF_IV_forw1/2 and bisBDNF_IV_rev; Sequencing: BDNF_IV_seq). Refer to table 1 for primer sequences.

Statistical analysis

The methylation of each of the 11 CpGs in the CpG island was assessed using the Epigenetic Sequencing Methylation analysis Software (ESME) (Lewin et al, 2004) which compares each methylation site to the original sequence of the promoter. To analyze the effect of antidepressant treatment on BDNFIV methylation, mixed linear models for repeated measurements were performed including the factors: CpG position, drugs (Venlafaxine/ Fluoxetine), time point (0.5 h, 2 h, 24 h and 48 h) and drug concentration (5 μ M and 10 μ M for Fluoxetine and 10 μ M and 50 μ M for Venlafaxine). For the model assessing the effect

of DNMTs and nanaomycin, CpG position and methyl modulators were used as factors. Data were analyzed employing IBM SPSS Statistics for Windows, Version 21.0. (Armonk, NY: IBM Corp.) and illustrated using Graph Pad Prism 5 (Graph Pad Inc., San Diego, CA). All the luciferase data were analyzed using two-way ANOVA in GraphPad Prism 5.

Abbreviations

AD

Antidepressants

BDNF

Brain derived neurotrophic factor

CREB

cAMP response element binding protein

DNMT

DNA methyltransferase

MDD

Major depressive disorder

MeCP2

Methyl CpG binding protein 2

SSRI

Serotonin reuptake inhibitors

SNRI

Serotonin norepinephrine reuptake inhibitors

Declarations

Ethics approval and consent to participate

Not Applicable

Consent for publication

Not Applicable

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

In house funds

Authors' contributions

Conceptualization: H.F. and H.P.; formal analysis: H.F. and H.F.; investigation: H.P., A.Bo. and S.G; writing – original draft and preparation: H.P.; writing – review and editing: H.P., A.Bu and H.F. ; visualization: H.P.; supervision: H.F. All authors have read and agreed to the submitted version of the manuscript.

References

1. Kraus C, Kadriu B, Lanzenberger R, Zarate CA, Jr., Kasper S. Prognosis and improved outcomes in major depression: a review. *Translational psychiatry*. 2019;9(1):127. Epub 2019/04/05.
2. Pandarakalam JP. Challenges of Treatment-resistant Depression. *Psychiatr Danub*. 2018;30(3):273–84. Epub 2018/09/30.
3. Fuchikami M, Morinobu S, Segawa M, Okamoto Y, Yamawaki S, Ozaki N, et al. DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. *PLoS One*. 2011;6(8):e23881. Epub 2011/09/14.
4. Bjorkholm C, Monteggia LM. BDNF - a key transducer of antidepressant effects. *Neuropharmacology*. 2016;102:72–9. Epub 2015/11/01.
5. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. *Biological psychiatry*. 2003;54(7):703–9. Epub 2003/09/27.
6. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. *Genomics*. 2007;90(3):397–406. Epub 2007/07/17.
7. Boulle F, van den Hove DL, Jakob SB, Rutten BP, Hamon M, van Os J, et al. Epigenetic regulation of the BDNF gene: implications for psychiatric disorders. *Mol Psychiatry*. 2012;17(6):584–96. Epub 2011/09/07.
8. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. *Science*. 2003;302(5646):890–3. Epub 2003/11/01.
9. Hing B, Sathyaputri L, Potash JB. A comprehensive review of genetic and epigenetic mechanisms that regulate BDNF expression and function with relevance to major depressive disorder. *Am J Med Genet B Neuropsychiatr Genet*. 2018;177(2):143–67. Epub 2017/12/16.
10. Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME. CREB: a major mediator of neuronal neurotrophin responses. *Neuron*. 1997;19(5):1031–47. Epub 1997/12/09.

11. Gupta S, Kim SY, Artis S, Molfese DL, Schumacher A, Sweatt JD, et al. Histone methylation regulates memory formation. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2010;30(10):3589–99. Epub 2010/03/12.
12. Collins BE, Greer CB, Coleman BC, Sweatt JD. Histone H3 lysine K4 methylation and its role in learning and memory. *Epigenetics & chromatin*. 2019;12(1):7. Epub 2019/01/09.
13. Mitchelmore C, Gede L. Brain Derived Neurotrophic Factor: epigenetic regulation in psychiatric disorders. *Brain Res*. 2014;1586:162–72. Epub 2014/09/17.
14. Januar V, Saffery R, Ryan J. Epigenetics and depressive disorders: a review of current progress and future directions. *International journal of epidemiology*. 2015;44(4):1364–87. Epub 2015/02/27.
15. Januar V, Ancelin ML, Ritchie K, Saffery R, Ryan J. BDNF promoter methylation and genetic variation in late-life depression. *Translational psychiatry*. 2015;5:e619. Epub 2015/08/19.
16. Vialou V, Feng J, Robison AJ, Nestler EJ. Epigenetic mechanisms of depression and antidepressant action. *Annu Rev Pharmacol Toxicol*. 2013;53:59–87. Epub 2012/10/02.
17. Yu NK, Baek SH, Kaang BK. DNA methylation-mediated control of learning and memory. *Molecular brain*. 2011;4:5. Epub 2011/01/21.
18. Wolkowitz OM, Wolf J, Shelly W, Rosser R, Burke HM, Lerner GK, et al. Serum BDNF levels before treatment predict SSRI response in depression. *Progress in neuro-psychopharmacology & biological psychiatry*. 2011;35(7):1623–30. Epub 2011/07/14.
19. Zheleznyakova GY, Cao H, Schioth HB. BDNF DNA methylation changes as a biomarker of psychiatric disorders: literature review and open access database analysis. *Behavioral and brain functions: BBF*. 2016;12(1):17. Epub 2016/06/09.
20. Ikegame T, Bundo M, Murata Y, Kasai K, Kato T, Iwamoto K. DNA methylation of the BDNF gene and its relevance to psychiatric disorders. *Journal of human genetics*. 2013;58(7):434–8. Epub 2013/06/07.
21. Tadic A, Muller-Engling L, Schlicht KF, Kotsiari A, Dreimuller N, Kleimann A, et al. Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. *Mol Psychiatry*. 2014;19(3):281–3. Epub 2013/05/15.
22. Lieb K, Dreimuller N, Wagner S, Schlicht K, Falter T, Neyazi A, et al. BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response. *Frontiers in psychiatry*. 2018;9:511. Epub 2018/11/22.
23. Wang P, Zhang C, Lv Q, Bao C, Sun H, Ma G, et al. Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients. *European journal of clinical pharmacology*. 2018;74(8):1011–20. Epub 2018/05/12.
24. Webb LM, Phillips KE, Ho MC, Veldic M, Blacker CJ. The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review. *International journal of molecular sciences*. 2020;21(3). Epub 2020/02/06.
25. Kleimann A, Kotsiari A, Sperling W, Groschl M, Heberlein A, Kahl KG, et al. BDNF serum levels and promoter methylation of BDNF exon I, IV and VI in depressed patients receiving electroconvulsive

- therapy. *J Neural Transm (Vienna)*. 2015;122(6):925–8. Epub 2014/11/13.
26. Klug M, Rehli M. Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector. *Epigenetics*. 2006;1(3):127–30. Epub 2007/10/30.
 27. Shieh PB, Hu SC, Bobb K, Timmusk T, Ghosh A. Identification of a signaling pathway involved in calcium regulation of BDNF expression. *Neuron*. 1998;20(4):727–40. Epub 1998/05/15.
 28. West AE, Chen WG, Dalva MB, Dolmetsch RE, Kornhauser JM, Shaywitz AJ, et al. Calcium regulation of neuronal gene expression. *Proceedings of the National Academy of Sciences of the United States of America*. 2001;98(20):11024–31. Epub 2001/09/27.
 29. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. Ca²⁺ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. *Neuron*. 1998;20(4):709–26. Epub 1998/05/15.
 30. Blendy JA. The role of CREB in depression and antidepressant treatment. *Biological psychiatry*. 2006;59(12):1144–50. Epub 2006/02/07.
 31. Ausio J. MeCP2 and the enigmatic organization of brain chromatin. Implications for depression and cocaine addiction. *Clinical epigenetics*. 2016;8:58. Epub 2016/05/24.
 32. Zhou Z, Hong EJ, Cohen S, Zhao WN, Ho HY, Schmidt L, et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent *Bdnf* transcription, dendritic growth, and spine maturation. *Neuron*. 2006;52(2):255–69. Epub 2006/10/19.
 33. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science*. 2008;320(5880):1224–9. Epub 2008/05/31.
 34. Schwartzman O, Tanay A. Single-cell epigenomics: techniques and emerging applications. *Nature reviews Genetics*. 2015;16(12):716–26. Epub 2015/10/16.
 35. Duan Z, Lu J. DNA Methyltransferases in Depression: An Update. *Frontiers in psychiatry*. 2020;11:538683. Epub 2020/10/27.
 36. Chen ZX, Mann JR, Hsieh CL, Riggs AD, Chedin F. Physical and functional interactions between the human DNMT3L protein and members of the de novo methyltransferase family. *Journal of cellular biochemistry*. 2005;95(5):902–17. Epub 2005/04/30.

Tables

Table 1.

Name	Sequence (5' 3')
Inf-BDNF-pCpGL Fw	GTGGATCCAGATCTT <u>ATTCCTCTGATACCCAG</u>
Inf-BDNF-pCpGL Rv	CTCCATGGACTAAGCT <u>CCACCTTTTCAGTCAC</u>
pCpGL-seq_Fw	AAAGGAATTCCTGCAGGACTAGTG
pCpGL-seq_Rv	TTGGCATCCTCCATGGACTAAGCT
bisBDNF_IV_forw1:	GGGGGAGGATTAATTGAGTTAGTTTTG
bisBDNF_IV_forw2:	TTTGTTGGGGTTGGAAGTGAAAAT
bisBDNF_IV_rev:	ATA TAT ACT CCT TCT ATT CTA CAACAA
BDNF_IV_seq:	ACAAAAAATTTTCATACTAA
Inf-DNMT1-Halo-Fw	TCACTATAGGGCTAGC <u>AGATGCCGGCGCGTACCGCC</u>
Inf-DNMT1-Halo-Rv	TCCGCGGTAGGAATTC <u>GTCCTTAGCAGCTTCCTCCTCCTTTA</u>
CpG87-mut-Fw	TCTGGTAATTmCGTGCACTAGAG
CpG87-mut-Rv	ATCAAATTCAGCGCATTTAAAATG
CpG35_NEB-mut-Fw	TGACAGCGCAmCGTCAAGGCAC
CpG35_NEB-mut-Rv	TATGATACCTCCGCTGCC
CpG39_NEB-mut-Fw	CATATGACAGmCGCACGTCAAGGC
CpG-39_NEB-mut-Rv	ATACCTCCGCTGCCTCGA
CpG87-NEB-Control-Fw	TCTGGTAATTCGTGCACTAGAG
CpG87-NEB-Control-Rv	ATCAAATTCAGCGCATTTAAAATG

Figures

Fig. 1




Figure 1

BDNF exon IV schematics. Sequence of the BDNFIV promoter analyzed for methylation. Primers (blue) and the CpGs (red) are highlighted. CpG -39 and -35 encompasses the cAMP Response Element (CRE). CpGs and numbered with respect to exon IV.

Fig. 2




Figure 2

a) Effect of antidepressants on BDNF exon IV promoter activity. The antidepressants at the given concentration decrease the promoter activity: Venlafaxine (50 µM, $p < 0.001$), Fluoxetine (10 µM, $p < 0.05$), Mirtazapine (50 µM, $p < 0.05$) and Lithium carbonate (3 mM, $p < 0.01$). Methylation reduces the promoter activity ($P < 0.0001$). There is no significant reduction in promoter activity on AD treatment in methylated fragment.

Fig. 3




Figure 3

Effect of single CpG methylation on BDNF exon IV promoter activity. Methylation at CpG position -35 and -87 and -39 does not show any significant change in promoter activity in control condition. In the cells treated with ADs, CpG -39 methylation significantly increases the promoter activity ($P < 0.0001$). Methylation at CpG -35 and -87 had no significant effect.

Fig. 4




Figure 4

Antidepressants increase BDNFIV promoter methylation. Venlafaxine at 50 μM significantly increases BDNF IV promoter methylation in comparison to 10 μM (* $P < 0.0001$) and 10 μM Fluoxetine in comparison to 5 μM (# $P = 0.025$)

Fig. 5a




Fig. 5b




Figure 5

Effect of DNMT overexpression on BDNF exon IV promoter activity. a) DNMT 3a overexpression significantly increases BDNF promoter activity ($P < 0.0001$). DNMT3b and DNMT1 do not have any significant effect. b) Venlafaxine further increases the DNMT3a mediated increase in promoter activity ($P < 0.01$). Fluoxetine has no significant effect.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [suppfig.pdf](#)